title: Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update.
abstract: Actinic keratosis is one of the most common dermatological diagnoses worldwide, especially among the elderly, fair-skinned, and immunocompromised, and is associated with a risk of transformation to skin cancer. With actinic keratosis and skin cancer prevalence increasing as the aged population expands in the US, optimizing treatment strategies may produce cost savings for the healthcare system. Since the time of our last review in 2008, investigation of the economic considerations in treating actinic keratosis has advanced. To provide an update of treatment cost effectiveness and to review factors relating to the costs of care, we conducted a systematic review of pharmacoeconomic publications since December 2008. We identified 11 pharmacoeconomic studies, with one cost-of-treatment, five cost-effectiveness, and five cost-utility analyses. Photodynamic therapy (PDT) was well tolerated and produced a favorable cosmetic outcome in most studies. Ingenol mebutate, the newest but most expensive topical field therapy, 5-fluorouracil, and PDT were the most cost-effective treatments in our review. Patient adherence to therapy and the management of adverse effects were significant contributors to treatment costs. In the US, treatment guidelines and formalized cost-effectiveness analyses for actinic keratosis are absent from the recent literature. Future pharmacoeconomic investigation will depend on up-to-date comparative efficacy data, as well as clarification of rates of, and management strategies for, adverse effects, therapeutic non-adherence, and lesion recurrence.
authors: Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157-1071, USA.
authors: Spencer M
authors: SM
authors: Vale
authors: Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157-1071, USA.
authors: Dane
authors: D
authors: Hill
authors: Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157-1071, USA. sfeldman@wakehealth.edu.|Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA. sfeldman@wakehealth.edu.|Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA. sfeldman@wakehealth.edu.
authors: Steven R
authors: SR
authors: Feldman
mesh_terms: D000368:Aged; D003362:Cost-Benefit Analysis; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D017850:Economics, Pharmaceutical; D006801:Humans; D055623:Keratosis, Actinic / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D055118:Medication Adherence; D010778:Photochemotherapy / Q000009:adverse effects / Q000191:economics / Q000379:methods*; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D012878:Skin Neoplasms / Q000209:etiology / Q000517:prevention & control
chemical_list: D003879:Dermatologic Agents